Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Ask ADVFN Intelligence (AI)
First patient enrolled in Pivotal's POMEGA Phase IIa clinical trial with PVT-100 PR Newswire WOODBRIDGE, ON, June 4, 2015 WOODBRIDGE, ON, June 4, 2015 /PRNewswire/ - Pivotal Therapeutics Inc...
Pivotal Therapeutics Announces First Quarter Financial Results PR Newswire WOODBRIDGE, ON, June 1, 2015 WOODBRIDGE, ON, June 1, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE:...
Pivotal Therapeutics Inc. is to be Featured on CEO Clips on CBC's The Documentary Channel PR Newswire WOODBRIDGE, May 11, 2015 WOODBRIDGE, May 11, 2015 /PRNewswire/ - Pivotal Therapeutics...
Pivotal Therapeutics Announces 2014 Financial Results PR Newswire WOODBRIDGE, ON, April 30, 2015 WOODBRIDGE, ON, April 30, 2015 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CSE: PVO...
Pivotal receives Health Canada approval to expand the indication of OMAZEN® to include products with claims to maintain and support cardiovascular health and normal triglyceride levels PR...
Pivotal executes Memorandum of Understanding for exclusive distribution of Benefishial™ line of products in Korea PR Newswire WOODBRIDGE, ON, April 15, 2015 WOODBRIDGE, ON, April 15, 2015...
Pivotal Therapeutics and French University Hospital of Strasbourg Announce POMEGA Trial Chief Investigator Dr. Yannick Georg Laureate of EUR 30,000 French Interregional Clinical Research and...
Pivotal Receives Notice of Allowance For U.S. Patent Related to a Kit for the Dietary Management of Cardiovascular Patients That Includes VASCAZEN® and an Omega-3 Fatty Acid Diagnostic Assay PR...
Pivotal Receives Notice of Allowance For U.S. Patent Related to a Kit for the Dietary Management of Cardiovascular Patients That Includes VASCAZEN® and an Omega-3 Fatty Acid Diagnostic...
Pivotal Therapeutics announces payment of interest on outstanding convertible notes PR Newswire WOODBRIDGE, ON, March 26, 2015 WOODBRIDGE, ON, March 26, 2015 /PRNewswire/ - Pivotal Therapeutics...
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0.0018 | 0.0018 | 0.0018 | 0 | 0 | CS |
| 26 | 0 | 0 | 0.0018 | 0.0018 | 0.0018 | 0 | 0 | CS |
| 52 | 0 | 0 | 0.0018 | 0.0018 | 0.0018 | 0 | 0 | CS |
| 156 | 0.0008 | 80 | 0.001 | 0.0021 | 1.0E-6 | 29419 | 0.00023157 | CS |
| 260 | -0.0002 | -10 | 0.002 | 0.16 | 1.0E-6 | 28800 | 0.02545146 | CS |
| Symbol | Price | Vol. |
|---|---|---|
| SPRVSupurva Healthcare Group Inc (PK) | US$ 0.0001 (-50.00%) | 163.23M |
| ASIIAccredited Solutions Inc (PK) | US$ 0.0006 (33.33%) | 152.19M |
| CBGLCannabis Global Inc (PK) | US$ 0.0001 (100.00%) | 149.39M |
| GRLFGreen Leaf Innovations Inc (PK) | US$ 0.0001 (0.00%) | 118.61M |
| ABQQAB International Group Corporation (PK) | US$ 0.0011 (10.00%) | 103.11M |
makinezmoney
6 years ago
makinezmoney
7 years ago
makinezmoney
7 years ago
makinezmoney
7 years ago
chaostrader
10 years ago
detuna
10 years ago
ListenToMe
10 years ago
BingBing90
11 years ago
chaostrader
11 years ago
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
